Home > Clinical Trials > Phase II Study of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Metastatic Gastric Cancer

Phase II Study of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Metastatic Gastric Cancer

Purpose

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.

Eligibility

To participate in this study, you must be at least 18 years old and have:

  • Histologically confirmed diagnosis of advanced or metastatic gastric carcinoma or adenocarcinoma of the gastroesophageal junction
  • Measurable disease and an ECOG performance status of </= 2
  • Adequate bone marrow reserve, hepatic, renal, and cardiovascular function

Exclusion Criteria

You will not be included in the study if you are pregnant or breastfeeding, HIV positive, or have brain metastases or any uncontrolled intercurrent illness.  

You will also be exluded if you have received:

  • Rradiation to >/=25 percent of bone marrow within 14 days of GSK1363089
  • More than two prior anti-cancer therapies
  • Prior treatment with a c-met inhibitor or antibodies against HGF

For more information, contact the clinical research coordinator at 919-668-1861.


(REF# 0864)